title: Development of effective cancer vaccine using targeting system of antigen protein to APCs.
abstract: OBJECTIVE
  To develop a novel cancer vaccine using the targeting system of antigen protein to antigen-presenting cells (APCs) for efficient and safe cancer therapy.
  
  
  METHODS
  The novel delivery system was constructed with antigen protein, benzalkonium chloride (BK), and γ-polyglutamic acid (γ-PGA), using ovalbumin (OVA) as a model antigen protein and evaluating its immune induction effects and utilities for cancer vaccine.
  
  
  RESULTS
  BK and γ-PGA enabled encapsulation of OVA and formed stable anionic particles at nanoscale, OVA/BK/γ-PGA complex. Complex was taken up by dendritic cell line DC2.4 cells efficiently. We subcutaneously administered the complex to mice and examined induction of IgGs. The complex induced not only Th2-type immunoglobulins but also Th1-type immunoglobulins. OVA/BK/γ-PGA complex inhibited tumor growth of E.G7 cells expressing OVA regularly; administered OVA/BK/γ-PGA complex completely rejected tumor cells.
  
  
  CONCLUSIONS
  The novel vaccine could be platform technology for a cancer vaccine.
authors: Department of Drug Delivery Research Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
authors: Tomoaki
authors: T
authors: Kurosaki
authors: Takashi
authors: T
authors: Kitahara
authors: Tadahiro
authors: T
authors: Nakamura
authors: Koyo
authors: K
authors: Nishida
authors: Shintaro
authors: S
authors: Fumoto
authors: Yukinobu
authors: Y
authors: Kodama
authors: Hiroo
authors: H
authors: Nakagawa
authors: Norihide
authors: N
authors: Higuchi
authors: Hitoshi
authors: H
authors: Sasaki
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D001548:Benzalkonium Compounds / Q000737:chemistry; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002460:Cell Line; D003713:Dendritic Cells / Q000276:immunology; D016503:Drug Delivery Systems; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control*; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011099:Polyglutamic Acid / Q000737:chemistry
chemical_list: D001548:Benzalkonium Compounds; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D011099:Polyglutamic Acid; D010047:Ovalbumin